US 20200231652A1

(19) United States

(12) Patent Application Publication

(10) Pub. No.: US 2020/0231652 A1

(43) Pub. Date: Jul. 23, 2020

Zwaagstra et al.

(54) TGF-B-RECEPTOR ECTODOMAIN FUSION MOLECULES AND USES THEREOF

(71) Applicant: **National Research Council of Canada**, Ottawa (CA)

(72) Inventors: **John C. Zwaagstra**, Laval (CA); **Traian Sulea**, Kirkland (CA); **Maria Jaramillo**, Beaconsfield (CA); **Maureen D. O'Connor**, Beaconsfield (CA); **Anne E.G. Lenferink**, Lorraine (CA)

(73) Assignee: **National Research Council of Canada**, Ottawa, ON (CA)

(21) Appl. No.: **15/755,595**

(22) PCT Filed: **Aug. 31, 2016**

(86) PCT No.: **PCT/IB2016/055204**

§ 371 (c)(1),
(2) Date: **Feb. 27, 2018**

Related U.S. Application Data

(60) Provisional application No. 62/212,058, filed on Aug. 31, 2015.

Publication Classification

(51) **Int. Cl.**

C07K 14/71	(2006.01)
C07K 16/22	(2006.01)
A61P 35/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 14/71*** (2013.01); ***C07K 16/22*** (2013.01); *A61K 2039/505* (2013.01); *C07K 2319/30* (2013.01); *C07K 2317/94* (2013.01); ***A61P 35/00*** (2018.01)

(57) **ABSTRACT**

The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-beta) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.

Specification includes a Sequence Listing.

T2m

IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKP
QEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMC
SCSSDECNDNIIFSEEYNTSNPD

T22d35



IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKP
QEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMC
SCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVR
FSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILE
DAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD